Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:38:34.471Z.
Consensus retrieved: 2026-10-06T14:52:19.561Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:38:34.471Z.
Quote observation: 2026-10-06T16:35:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9c381dd31ebabd106cc7de4c03b90562a614b66fe6a61eecf39b5faa645a8d70
Forward PE Ratio (N/A) = Dated Quote Price ($1.32) / Consensus Forward EPS ($-1.38)
FORWARD PE RATIO
N/A
Organogenesis Holdings Inc.
Market Cap
$170.49M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Organogenesis Holdings Inc. (ORGO) | $170.49M | N/A |
| Cue Biopharma, Inc. (CUE)vs › | $171.59M | N/A |
| Nkarta, Inc. (NKTX)vs › | $170.28M | N/A |
| MediWound Ltd. (MDWD)vs › | $169.88M | N/A |
| ProQR Therapeutics N.V. (PRQR)vs › | $172.71M | N/A |
| Precision BioSciences, Inc. (DTIL)vs › | $173.89M | N/A |
| Compass Therapeutics, Inc. (CMPX)vs › | $174.15M | N/A |
| OptimizeRx Corp. (OPRX)vs › | $166.73M | 9.91 |
| Journey Medical Corporation (DERM)vs › | $177.66M | N/A |
| Quanterix Corporation (QTRX)vs › | $163.22M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $1.32, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.38 | $-1.54 – $-1.22 | 1 | n/m |
| 2027-12-31 | $-0.31 | $-0.39 – $-0.23 | 2 | n/m |
| 2028-12-31 | $-0.20 | $-0.24 – $-0.16 | 2 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
